Form 4: Acadia Pharmaceuticals Executive Mark Schneyer Reports Stock Transactions

Mark Schneyer, EVP and CFO of Acadia Pharmaceuticals, reports acquisition and disposal of company stock and derivative securities.

Summary

• Mark Schneyer, the EVP and Chief Financial Officer of Acadia Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On March 25, 2024, Schneyer acquired 10,550 shares of common stock upon vesting of performance stock units at a price of $0.
• On March 27, 2024, Schneyer disposed of 5,434 shares of common stock at $17.90 per share.
• Following these transactions, Schneyer directly owns 26,183 shares of Acadia Pharmaceuticals common stock.
• Schneyer also acquired 80,564 stock options with an exercise price of $17.84, vesting incrementally starting March 25, 2025, and expiring on March 24, 2034.
• Additionally, Schneyer acquired 24,714 restricted stock units that vest in four equal annual installments beginning March 25, 2025.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing reflects routine transactions related to executive compensation. The sale of shares to cover taxes is a common occurrence and doesn't necessarily indicate a negative outlook.

Positives

• The acquisition of stock options and restricted stock units suggests a long-term commitment to the company by the executive.

Negatives

• The sale of 5,434 shares, although to cover withholding taxes, could be perceived negatively by some investors.

Risks

• The vesting of stock options and restricted stock units could potentially dilute existing shareholders' equity.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of the stock options and restricted stock units suggest a multi-year horizon for executive compensation.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Executive compensation packages including stock options and restricted stock units are standard practice in the pharmaceutical industry.
• Vesting schedules and performance-based equity grants are common mechanisms to align executive incentives with shareholder value creation.
• Comparing the size and terms of these grants to those of executives at comparable companies like Biogen, Amgen, or Vertex Pharmaceuticals would provide further context.

Stakeholder Impact

• The vesting of equity awards aligns management's interests with those of shareholders.
• The sale of shares to cover taxes has a minimal impact on the overall market.

Key Dates